Search Results for: carcinoid syndrome

Zebra

Now Recruiting: Carcinoid Syndrome Patients to Participate in Clinical Trial

June 17, 2011

Ipsen is recruiting patients with a history of carcinoid syndrome to participate in a clinical study to evaluate the effect of Somatuline® Depot (Lanreotide Autogel),  a somatostatin analog (SSTa) similar to octreotide, on the control of symptoms …

READ MORE
Arthur T. Sands, MD, PhD, President and Chief Executive Officer, Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc. Clinical Trial Recruiting Carcinoid Syndrome Patients

September 10, 2010

Patients with carcinoid syndrome, whose symptoms are not managed by octreotide therapy, are being recruited for a Phase 2 clinical trial of Lexicon Pharmaceuticals’ LX1606 (a.k.a. LX1032).  The trial has been given Fast Track status in the U.S. and …

READ MORE

Carcinoid Syndrome Clinical Trial to Be Featured on Webcast

April 6, 2010

Lexicon Pharmaceuticals’ clinical trial LX1032 for carcinoid syndrome will be among the clinical programs that are reviewed in-depth on April 8, 2010 when the company holds its Annual R&D Day from 7:30 to 11:00 am, Eastern Time, in New York City. …

READ MORE

Sandostatin Mobile Administration Program for Carcinoid Syndrome Patients

February 18, 2010

If you are a carcinoid patient who needs Sandostatin® LAR Depot injections, you may be eligible for the Mobile Administration Program.  This program helps alleviate the stress of driving to a doctor’s office (or finding one where you live or while on vacation),…

READ MORE

Is It Irritable Bowel Syndrome or Carcinoid Cancer? Think Zebras, Not Horses

June 21, 2010

So often misdiagnosed as irritable bowel syndrome or Crohn’s disease, carcinoid cancer is a diagnosis where doctors are thinking zebras not horses.  The saying goes back to medical school when students are taught to consider the uncommon.  “Ninety-nine…

READ MORE
Ask the NET Expert Side Banner v.3

News and Notes from the Carcinoid Cancer Foundation, March 2022

March 20, 2022
Ask the NET Expert — A New Web-Based Program

The Carcinoid Cancer Foundation is excited to have launched in February a new web-based program for the neuroendocrine tumor (NET) community – Ask the NET Expert. Each month, we are featuring a different…

READ MORE
App Carcinoid NETs Updated_2

Carcinoid NETs Health Storylines App Launches New Features

August 23, 2018

Living with Neuroendocrine Tumors (NETs) and Carcinoid Syndrome is not easy but two new features on the Carcinoid NETs Health Storylines App aim to make it a little easier.

 

Zebra Tales presents real stories about real life experiences by people…

READ MORE
Acronym wordcloud_2

Acronyms Used in the Carcinoid and Neuroendocrine Tumor Community

April 19, 2017

(Updated 2022)

Whether you are newly diagnosed, a friend or family member of a carcinoid/neuroendocrine tumor (NET) patient, or someone living with the disease for a long time, the language used in the carcinoid/NET community, especially the acronyms,…

READ MORE

Carcinoid Cancer Foundation Announces Appointment of Edward M. Wolin, MD as Co-Medical Director and Board Member

June 24, 2016

Edward M. Wolin, MD, an internationally renowned neuroendocrine cancer specialist and medical oncologist, has been named Co-Medical Director and Board member of the Carcinoid Cancer Foundation (CCF) in White Plains, New York.  Dr. Wolin is Director

READ MORE
Diane Reidy Lagunes, MD, Memorial Sloan Kettering_2

News and Notes for the Carcinoid and Neuroendocrine Tumor Community, March 2016

March 23, 2016

Breaking News from Advanced Accelerator Applications (AAA) about PRRT Treatment— Advanced Accelerator Applications announced on March 23 that the company has initiated an expanded access program (EAP) in the United States for the investigational…

READ MORE